Loading company…
Synaffix BV is a Dutch biotechnology company that licenses antibody-drug conjugate (ADC) technology for cancer therapies.
Synaffix BV, founded in 2010 in Oss, Netherlands, develops biopharmaceutical technologies centred on antibody-drug conjugates (ADCs). Its platform, built around the antibody glycan, is licensed to pharmaceutical partners for cancer treatments. The company has completed 2 deals, most recently a trade sale to Lonza Group Ltd. on June 1, 2023, for EUR 100 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in